ISSN: 2167-7700
+44 1223 790975
Yuko Kitagawa
Japan
Research Article
Oral Adjuvant Chemotherapy with S-1 or Uracil-tegafur versus Surgery
Alone in Patients with Biliary Tract Cancer
Author(s): Osamu Itano, Naokazu Chiba, Masatsugu Ishii, Masahiro Shinoda, Minoru Kitago, Yuta Abe, Taizo Hibi, Hiroshi Yagi, Motohide Shimazu and Yuko Kitagawa
Osamu Itano, Naokazu Chiba, Masatsugu Ishii, Masahiro Shinoda, Minoru Kitago, Yuta Abe, Taizo Hibi, Hiroshi Yagi, Motohide Shimazu and Yuko Kitagawa
Abstract Objective: We compared the influence of postoperative adjuvant chemotherapy with oral anticancer drugs (S-1 or uracil-tegafur [UFT]) and the influence of surgery alone on overall survival (OS) and disease-free survival (DFS) in patients with biliary tract cancer. Methods: This retrospective study included 108 patients with gallbladder cancer (n=22) or bile duct cancer (n=86), who underwent curative resection. The patients were divided into surgery alone (n=58), UFT (n=39; 400 mg/m2/day), and S-1 groups (n=11; 80 mg/m2, days 1?28, twice daily), and outcomes and adverse effects were compared. Results: The 2-year DFS rate was significantly higher in the S-1 group than in the surgery alone group for all patients (72.7% vs. 32.8%, p=0.046). For the patients with gallbladder cancer, the 2-year OS and DFS rates were significantly higher in the UFT group than in the surgery alone group .. View More»
DOI:
10.4172/2167-7700.1000174